Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Learn more

  • Federal contracts (SAM.gov)The Ultimate Guide to SAM.gov Registration
  • Before you submitBid Response: 3 Common Mistakes When Submitting an RFP
More chemical manufacturing bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Bids
  3. ›Federal
  4. ›Contracts
  5. ›Non-Competitive Combined/Synopsis for L-Glutamic Acid
More bids in Maryland →

U.S. Department Of Health And Human Services·Maryland

Non-Competitive Combined/Synopsis for L-Glutamic Acid

Closes 9/8/2026$500 – $3kSole Source
Bid source

This opportunity has closed.

Bid Banana tracks 1.6M+ bids and awards across all 50 states. Save a search and we'll email your new matches, daily or weekly — so the next one reaches you with time to bid.

Get alerted next time

Description

The NIH National Institute of Mental Health (NIMH) is seeking a single‑source, firm‑fixed‑price purchase of 13C‑labeled L‑Glutamic Acid (99% purity, 1 g) from Sigma‑Aldrich to support in‑vivo carbon‑13 magnetic resonance spectroscopy research. The product is critical for enhancing signal intensity in brain‑metabolism studies; without it, the institute’s MR spectroscopy capabilities would be severely limited. This is a non‑competitive acquisition under FAR 12.603 and will be awarded directly to the vendor. The delivery location is NIH, NIMH, Bethesda, MD. • Item: 13C‑labeled L‑Glutamic Acid, 99% purity, 1 g (Sigma‑Aldrich product code 13C2). • Delivery: NIH, NIMH, 10 Cener Drive, Bldg. 10, Bethesda, MD 20892. • Contract type: Firm‑fixed‑price, sole‑source, non‑competitive. • Submission deadline: 8 Sep 2026, 10:00 AM EDT (electronic response to [email protected]). • Required documentation: UEI, TIN, size certification, SAM registration, product specifications, pricing breakdown, shipping terms. • Evaluation criteria: Technical capability, price, past performance, delivery schedule, warranty, and compliance with specifications.

Attached files

The solicitation documents live at the source — open the bid source above to download them.

Contact

Brian Lind

[email protected]

(000) 000-0000

Key dates

Opened
8/31/2026
Closes
9/8/2026

Last updated

Details

Type
Sole Source
Industry
Chemical Manufacturing
NAICS
325180
Solicitation №
75N98026Q01122

Budget estimate

$500 – $2,500

The solicitation does not disclose a contract value. A 13C‑enriched L‑Glutamic Acid standard of 1 g typically costs between $400 and $2,000 depending on purity, quantity, and shipping. Assuming a unit price near the high end of that range plus standard shipping and handling, the total contract is likely in the low‑to‑mid‑four‑figure range (approximately $500–$2,500). Factors influencing the final amount include any volume discounts, expedited shipping fees, and applicable federal taxes or fees.

AI estimate from the solicitation

Similar opportunities

Matched by Bid Banana AI™

Bid Banana · 1.6M+ bids and awards 🍌

You found this one too late. Don't find the next one too late.

Bid Banana searches open government bids across all 50 states, updated daily. Save a search once and we email you your new matches, daily or weekly, while there is still time to win them.

1.6M+
bids & awards
All 50
states
4,000+
agencies
Start your 7-day free trial

Plans from $49.99/month. Cancel anytime, no setup fees.

Built by The Bid Lab, answering RFPs since 2017.

U.S. Food and Drug Administration·United States of America

Top match · 65%

Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed

Rolling / TBD closeOpened 11/24/2023

U.S. Environmental Protection Agency·United States of America

64% match

Combined synopsis/solicitation for general lab sup

Closes 10/16/2026Opened 10/8/2026

U.S. Food and Drug Administration·United States of America

62% match

Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)

Rolling / TBD closeOpened 11/24/2023

U.S. National Institutes of Health·United States of America

61% match

Limited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 - Clinical Trials Required)

Closes 11/5/2027Opened 10/28/2024

U.S. Food and Drug Administration·United States of America

61% match

Cooperative Agreement for Long Term Data Collection on Antimicrobial Use in Animals (U01) Clinical Trial Not Allowed

Rolling / TBD closeOpened 11/29/2023

U.S. Department Of Defense·Pennsylvania

61% match

MONOPLUSE COMBINER

Closes 10/19/2026Opened 9/2/2026

U.S. Food and Drug Administration·United States of America

60% match

Retail Food Safety Regulatory Association Collaboration

Rolling / TBD closeOpened 8/4/2025

U.S. National Institutes of Health·United States of America

60% match

Limited Competition: Resources and Workforce Development for the Regional Biocontainment Laboratories

Closes 9/29/2027Opened 6/24/2026

U.S. Food and Drug Administration·United States of America

60% match

Retail Food Safety Regulatory Association Collaboration CAP

Rolling / TBD closeOpened 8/14/2024

U.S. National Institutes of Health·United States of America

60% match

Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)

Closes 1/7/2028Opened 10/4/2024

U.S. Food and Drug Administration·United States of America

60% match

Cooperative Agreement to Support a Human Abuse Potential Study of Botanical Kratom (U01 Clinical Trial Required)

Rolling / TBD closeOpened 11/24/2023

U.S. Department Of Defense·Virginia

59% match

DLA-SM Broad Agency Announcement

Closes 1/30/2029Opened 1/29/2026

U.S. National Institutes of Health·United States of America

59% match

Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)

Closes 10/9/2028Opened 4/9/2026

U.S. General Services Administration·Pennsylvania

59% match

Multiple Award Schedule

Closes 6/3/2031Opened 1/18/2023

U.S. National Institutes of Health·United States of America

59% match

Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)

Closes 9/25/2028Opened 6/9/2025

U.S. National Institutes of Health·United States of America

59% match

Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)

Closes 5/25/2027Opened 2/11/2026

U.S. National Institutes of Health·United States of America

59% match

Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science

Closes 1/24/2027Opened 7/20/2026

U.S. National Institutes of Health·United States of America

59% match

CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)

Closes 11/5/2028Opened 6/30/2025

U.S. Food and Drug Administration·United States of America

59% match

Center for Research on Complex Generics (U18) Clinical Trials Optional

Rolling / TBD closeOpened 8/14/2024

U.S. Department Of Defense·United States of America

59% match

BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development - HT9425-23-S-SOC1

Closes 7/31/2028Opened 8/11/2023

U.S. Department Of Health And Human Services·United States of America

58% match

2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases

Closes 12/8/2026Opened 10/9/2026

Arkansas Department of Finance and Administration·Arkansas

58% match

Comprehensive Opioid Abuse Request For Application (RFA) – Category 4

Rolling / TBD closeOpened 12/5/2025

U.S. Food and Drug Administration·United States of America

58% match

Laboratory Flexible Funding Model (LFFM)

Closes 1/11/2028Opened 2/6/2025

U.S. Food and Drug Administration·United States of America

58% match

Novel approaches to support therapeutic development in ultra-rare cancers

Rolling / TBD closeOpened 8/4/2025

U.S. Food and Drug Administration·United States of America

58% match

Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01) Clinical Trials Allowed

Rolling / TBD closeOpened 8/14/2024